About Escient Pharmaceuticals
Escient Pharmaceuticals is a company based in San Diego (United States) founded in 2017 was acquired by Incyte in April 2024.. Escient Pharmaceuticals has raised $237.5 million across 3 funding rounds from investors including Incyte, TD Securities and Perceptive Advisors. The company has 44 employees as of December 31, 2021. Escient Pharmaceuticals offers products and services including EP262 and EP547. Escient Pharmaceuticals operates in a competitive market with competitors including Aclaris Therapeutics, Nimbus Therapeutics, Alpine Immune Sciences, Septerna and Upstream Bio, among others.
- Headquarter San Diego, United States
- Employees 44 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Escient Pharmaceuticals, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Escient Pharmaceuticals
Escient Pharmaceuticals offers a comprehensive portfolio of products and services, including EP262 and EP547. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Antagonist for MRGPRX2 targeting chronic urticaria and mast cell disorders
Antagonist for MRGPRX4 treating cholestatic pruritus
Unlock access to complete
Unlock access to complete
Funding Insights of Escient Pharmaceuticals
Escient Pharmaceuticals has successfully raised a total of $237.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $120 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series C — $120.0M
-
First Round
First Round
(09 May 2018)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2022 | Amount | Series C - Escient Pharmaceuticals | Valuation | New Enterprise Associates , Abingworth | |
| Sep, 2020 | Amount | Series B - Escient Pharmaceuticals | Valuation | Sanofi Ventures , Perceptive Advisors |
|
| May, 2018 | Amount | Series A - Escient Pharmaceuticals | Valuation | TCG , 5AM Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Escient Pharmaceuticals
Escient Pharmaceuticals has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Incyte, TD Securities and Perceptive Advisors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
Limited information is provided about Forge Life Science Partners.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Escient Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Escient Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Escient Pharmaceuticals Comparisons
Competitors of Escient Pharmaceuticals
Escient Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Nimbus Therapeutics, Alpine Immune Sciences, Septerna and Upstream Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| domain | founded_year | HQ Location |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for allergic and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Escient Pharmaceuticals
Frequently Asked Questions about Escient Pharmaceuticals
When was Escient Pharmaceuticals founded?
Escient Pharmaceuticals was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Escient Pharmaceuticals located?
Escient Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Escient Pharmaceuticals a funded company?
Escient Pharmaceuticals is a funded company, having raised a total of $237.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on May 09, 2018.
How many employees does Escient Pharmaceuticals have?
As of Dec 31, 2021, the latest employee count at Escient Pharmaceuticals is 44.
What does Escient Pharmaceuticals do?
Escient Pharmaceuticals was founded in 2017 in San Diego, United States. Small molecule-based therapeutics are developed by the company within the pharmaceutical sector, targeting inflammatory diseases. G protein-coupled receptor (GPCR) drugs are pursued for treating neuro-immuno-inflammatory and autoreactive conditions. Operations center on drug development for these therapeutic areas, with a focus on broad-range applications in immunology and neurology.
Who are the top competitors of Escient Pharmaceuticals?
Escient Pharmaceuticals's top competitors include Nimbus Therapeutics, Alpine Immune Sciences and Gossamer Bio.
What products or services does Escient Pharmaceuticals offer?
Escient Pharmaceuticals offers EP262 and EP547.
Who are Escient Pharmaceuticals's investors?
Escient Pharmaceuticals has 15 investors. Key investors include Incyte, TD Securities, Perceptive Advisors, Abingworth, and The Column Group.